A leading energy-based medical device company has announced the expansion of FoLix™ into Australia, marking the first time the FDA-cleared fractional non-ablative laser for hair loss will be available in the country.
Following a successful debut in the United States in June 2024, Lumenis is accelerating its international growth with the Australian launch of FoLix™, a non-invasive treatment designed to address hair loss in both men and women. The expansion represents a major milestone for the company as it seeks to broaden access to clinically proven, technology-driven hair restoration solutions worldwide.
FoLix™ uses a proprietary fractional, non-ablative laser technology specifically designed for scalp hair. By delivering precise laser pulses, the device stimulates hair follicles, improves blood circulation, and activates the body’s natural healing processes to support tissue regeneration. According to the company, visible results can be achieved in four to six monthly sessions, without the need for chemicals, injections, anesthesia, surgery, or recovery time.
The launch comes as hair loss continues to affect a significant portion of the global population. Industry data show that more than 85% of men and 50% of women experience some form of hair loss during their lifetime, often impacting self-confidence and overall quality of life.
“With FoLix™, we’re not just offering a treatment—we’re empowering people to reclaim their confidence and feel like their best selves,” said Tzipi Ozer-Armon, CEO of Lumenis. “The expansion into Australia marks a pivotal milestone in our mission to transform the hair loss space with a solution that is science-backed, safe, and clinically proven. Our recent NewBeauty and MEDTECH award wins further reinforce our commitment to accelerating global access to FoLix™.”
FoLix™ has gained traction across multiple international markets due to its ability to integrate easily into existing aesthetic and dermatology practices. As patient demand grows for non-surgical, low-discomfort treatments that fit seamlessly into busy lifestyles, the device has positioned itself as a leading option in the hair loss treatment landscape.
Dermatologists have also highlighted the treatment’s patient-friendly design. “This is an amazing treatment that, in my experience, is less painful than platelet-rich plasma therapies,” said Dr. Ronda Farah, a dermatologist based in Maple Grove, Minnesota. “It offers an effective option for hair stimulation without requiring ongoing medication.”
FoLix™ has received multiple industry accolades, including the 2025 MEDTECH Breakthrough Award for “Best New Dermatology Technology Solution,” recognizing its scientific innovation, patient-focused design, and measurable clinical impact. The device also earned NewBeauty’s 2025 Beauty Award for “Best Laser Treatment for Hair Loss,” underscoring its effectiveness and cutting-edge approach.
FoLix™ is indicated for adult men and women with Fitzpatrick skin types I to IV who are seeking a non-invasive solution for improving the appearance of scalp hair. By treating the scalp in a precise, grid-like pattern, the technology delivers targeted energy to stimulate circulation and enhance hair growth potential.
